Streetbeat News

Earnings

UP

Wheels Up Experience (NYSE:UP) reported Q2 EPS of $(0.14), a significant improvement from $(6.28) YoY. However, sales dropped 41.42% YoY to $196.28M from $335.06M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:30 pm

CABA

Cabaletta Bio reported a Q2 2024 GAAP EPS of $(0.56), missing the $(0.55) estimate. The company has $203.2M in cash, cash equivalents, and short-term investments as of June 30, 2024, which is expected to support operations into the first half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:30 pm

PEPG

PepGen (NASDAQ:PEPG) reported a Q2 EPS of $(0.87), missing the analyst consensus estimate of $(0.72) by 20.83%. This represents a 6.1% increase in losses compared to $(0.82) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:29 pm

VRDN

Viridian Therapeutics (NASDAQ: VRDN) reported Q2 2024 adjusted EPS of $(1.02), missing the analyst estimate of $(0.89) by 14.61%. The company also reported sales of $72.00K, missing the estimate of $86.15K by 16.43%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:29 pm

AURA

Aura Biosciences reported a Q2 2024 GAAP EPS of $(0.41), beating the estimate of $(0.46). The company has cash, cash equivalents, and marketable securities totaling $187.4 million, which are expected to fund operations into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:28 pm

HGV

Hilton Grand Vacations shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY24 adjusted EBITDA guidance.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:27 pm

ABNB

Airbnb Inc (NASDAQ:ABNB) is nearing a Death Cross, a bearish technical signal, following a disappointing Q2 earnings report and weak guidance for Q3. The stock has been on a downward spiral, falling 26.61% in the last month and 12.05% over the past five trading days. Technical indicators like MACD and RSI suggest a strongly bearish trend.

Portfolio Pulse from Surbhi Jain

August 08, 2024 | 12:27 pm

RAPT

RAPT Therapeutics (NASDAQ:RAPT) reported a Q2 EPS of $(0.71), beating the analyst consensus estimate of $(0.72) by 1.39%. This represents a 7.58% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:27 pm

BRNS

Barinthus Biotherapeutics (NASDAQ:BRNS) reported a Q2 EPS loss of $(0.43), missing the analyst estimate of $(0.41) by 4.88%. This is an improvement from the $(0.62) loss per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:27 pm

LLY

Eli Lilly (NYSE: LLY) reported strong Q2 earnings, with revenue of $11.3 billion, up 36% YoY, surpassing estimates. The growth was driven by increased sales of diabetes and weight loss drugs, particularly Mounjaro, Zepbound, Verzenio, Taltz, and Jardiance. The company raised its 2024 sales and EPS guidance, reflecting confidence in continued strong performance.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 12:26 pm